D
Candel Therapeutics, Inc. CADL
$5.88 $0.111.82% NASDAQ
Recommendation
Prev Close
$5.78
Volume
44,659
Avg Vol (90D)
851,788
Market Cap
$317.02M
Dividend & Yield
--
52-Week Range
$3.79 - $14.60
P/E (TTM)
--
EPS (TTM)
-$0.69
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Candel Therapeutics Funding Could Be A Game Changer For Trinity Capital (TRIN)
10/15/2025 - Simply Wall St
Candel Therapeutics (CADL) Secures $130M Loan to Boost Strategic Initiatives
10/14/2025 - GuruFocus
Small cap wrap: Millennial Potash, Nextech3D.ai, Candel Therapeutics, Charbone Hydrogen...
10/14/2025 - Proactive Investors - UK
Candel Therapeutics signs $130M term loan facility with Trinity Capital
10/14/2025 - SeekingAlpha.com: All News
Candel Therapeutics secures $130M loan facility to advance clinical pipeline
10/14/2025 - Proactive Investors - UK
Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer
10/14/2025 - Stocktwits News Feed
Candel Therapeutics (CADL) Secures $130 Million Loan to Propel Clinical Trials
10/14/2025 - GuruFocus
Candel Therapeutics (CADL) Unveils Promising Interim Results for CAN-3110
10/14/2025 - GuruFocus
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 ...
10/14/2025 - GuruFocus
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
10/14/2025 - GuruFocus
Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting ...
10/14/2025 - GuruFocus
Candel Therapeutics (CADL) Secures $130M Growth Capital for Cancer Treatments
10/14/2025 - GuruFocus
Candel Therapeutics secures $130M loan to advance cancer therapy trials
10/14/2025 - Proactive Investors - UK
Candel Therapeutics enters into $130M term loan facility
10/14/2025 - TipRanks Financial Blog
Candel Therapeutics announces interim data from phase 1b CAN-3110 trial
10/14/2025 - TipRanks Financial Blog
Candel Therapeutics announces interim data from phase 1b CAN-3110 trial
10/14/2025 - The Fly
Candel Therapeutics enters into $130M term loan facility
10/14/2025 - The Fly
Trinity Capital provides $130M in growth capital to Candel Therapeutics
10/14/2025 - The Fly
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
10/14/2025 - Globe Newswire
Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer
10/14/2025 - PR Newswire
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
10/14/2025 - Globe Newswire
Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now
10/13/2025 - SeekingAlpha
Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now
10/13/2025 - Seeking Alpha - Long Ideas
Candel Therapeutics (CADL, $6.19) RSI Indicator left the overbought zone on October 10, 2025
10/11/2025 - Tickeron - Stocks
Weiss Ratings Reiterates "Sell (D-)" Rating for Candel Therapeutics (NASDAQ:CADL)
10/10/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$34.49M
EBIT (TTM)
-$35.46M
Net Income (TTM)
-$22.14M
Balance Sheet
Total Assets (Q)
$105.97M
Total Debt (Q)
$8.34M
Total Liabilities (Q)
$15.76M
Book Value Per Share (Q)
$1.64
Cash Flow
Cash from Operations (TTM)
-$29.89M
Cash from Investing (TTM)
-$37.00K
Cash from Financing (TTM)
$109.16M
Net Change in Cash (TTM)
$79.23M
Filings
Filing Date
Thursday, August 14, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Loading...
Beta
1.18
7-Day Total Return
7.50%
30-Day Total Return
15.18%
60-Day Total Return
-11.84%
90-Day Total Return
-2.65%
Year to Date Total Return
-34.59%
1-Year Total Return
-1.18%
2-Year Total Return
553.33%
3-Year Total Return
135.20%
5-Year Total Return
--
52-week Low
Nov 15, 2024 - $3.79
52-week High
Dec 11, 2024 - $14.60
Valuation
Market Cap
$317.02M - Small Cap
Enterprise Value
$224.67M
Price/Sales (TTM)
--
Price/Book (Q)
3.51
Dividends and Shares
Shares Outstanding
51.49
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.candeltx.com
Phone Number
617 916 5445
Address
117 Kendrick Street
Needham, MA 02494
Country
United States
Year Founded
2003
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the... more
NASDAQ 10/15/2025 9:37AM Eastern Quotes delayed